ArticleAJR. American journal of roentgenology2015

RECIST 1.1 compared with RECIST 1.0 in patients with advanced renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.

Katherine M Krajewski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.